Purpose Silent corticotroph adenomas (SCAs) present clinically as non-functioning adenomas (NFAs) but are immunopositive for adrenocorticotrophic hormone (ACTH) without biochemical and clinical manifestation of hypercortisolism. Pathologic examination of resected NFAs that demonstrate positive ACTH and/or TPIT expression confirms its corticotroph lineage. SCAs comprise up to 20% of NFAs and exhibit a higher rate of recurrence. Studies of molecular mechanisms have generated multiple hypotheses on SCA tumorigenesis, pathophysiology, and growth that as yet remain to be proven. An improved understanding of their pathologic and clinical characteristics is needed. Methods A literature review was performed using PubMed to identify research reports and clinical case series on SCAs. Results Up to date findings regarding epidemiology, mechanisms of pathogenesis, differentiation, progression, and growth, as well as clinical presentation, postoperative course, and treatment options for patients with SCAs are presented. Pooled results demonstrate that 25-40% of cases show cavernous sinus invasion, preoperative hypopituitarism, new-onset hypopituitarism, and recurrence. Conclusion This article reviews the incidence, molecular pathology, and clinical behavior of these unique non-functioning pituitary corticotroph adenomas, and highlights the need for rigorous monitoring for recurrences and hypopituitarism in patients with SCAs.
Introduction
Silent corticotroph adenomas (SCAs) are pituitary adenomas that stain immunopositive for adrenocorticotrophic hormone (ACTH). However, unlike ACTH-secreting pituitary adenomas in patients with Cushing disease (CD), patients with SCA do not manifest biochemical or clinical evidence of hypercortisolism. Rather, SCAs present as clinically nonfunctioning adenomas (NFAs) and are resected due to mass effects. In a large registry of resected sellar masses, SCAs accounted for approximately 3% of pituitary adenomas and 5.5% of NFAs [1] . Some have reported incidence of SCA to be significantly higher than that of functional CD adenomas [2, 3] while others report a lower incidence [4, 5] , with an estimated 5-19% of adenomas classified preoperatively as NFAs later diagnosed as SCAs on pathologic examination of resected tissue [1] [2] [3] [6] [7] [8] [9] [10] [11] . The variability in rates of SCA likely depends on criteria used in each series. For example, with the addition of pituitary-restricted transcription factor (TPIT) immunostaining, ACTH-negative NFAs may be reclassified as SCAs. In one study, ACTH-positive tumors comprised 4.8% of pituitary adenomas, with 9.7% classified as Cushing disease tumors. However, when TPITpositive, ACTH-negative NFAs were classified as SCAs, the rate of these tumors increased to 7.7% [12] . Pooled cohorts accounting for such differences suggest that SCAs comprise 6.8% of pituitary surgeries [11] .
Pathologic characteristics
The 2017 World Health Organization (WHO) classification of pituitary adenomas defines corticotroph adenomas as those that arise from adenohypophyseal cells of TPIT lineage and that expresses ACTH and other proopiomelanocortin (POMC)-derived peptides [13] . Both functioning CD 1 3 adenomas and SCAs belong to the TPIT lineage [13] and TPIT expression is present in both tumor types [5, 12, 14, 15] .
As commercially available ACTH antibodies can also recognize POMC, immunostaining cannot clearly separate the cleaved ACTH(1-39) from pro-ACTH or POMC. Therefore, it will not provide information on whether ACTH measured in the pathology specimen and in the circulation is bioactive or bioinactive ACTH, pro-ACTH, or POMC. Indeed, patients with SCA have higher levels of bioinactive ACTH precursors compared with active ACTH, suggesting abnormal cleavage of POMC in these tumors [16] . This finding led to the suggestion that clinical symptoms of Cushing's syndrome in patients with corticotroph macroadenomas depends on the presence of ACTH , as well the type and quantity of ACTH precursors produced [16] .
Routine TPIT immunostaining of the specimen may be useful for better identifying SCAs [12, 13] . Of 119 hormonenegative null pituitary adenomas, 30% immunostained positive for TPIT. Re-staining these tumors for ACTH showed ACTH-positive cells originally thought to be normal corticotroph cells that were "trapped" within the tumor. Moreover, as these TPIT-positive tumors resembled SCAs in tumor aggressiveness and female preponderance, the authors suggest that ACTH immunostaining is not sufficient for pathologic diagnosis of SCA, and that TPIT immunostaining should be added to the diagnostic protocol [12] . Unfortunately, ACTH-TPIT co-localization was not performed in this study to determine whether TPIT is localized only to the "trapped" ACTH-secreting cells or whether it also localized to non-ACTH staining tumor cells; its presence in the latter would support the benefit of TPIT in the staining protocol to identify NFAs that are actually SCAs.
Another distinguishing characteristic of SCA is the absence of Crooke's hyalinization. Hyaline deposits of cytokeratin intermediate filaments in the cytoplasm of corticotroph cells occur following prolonged exposure to high circulating glucocorticoid levels; as SCAs are nonfunctional, Crooke's hyalinization occurs in CD but not in SCA [17, 18] .
2017 WHO classification also defined two types of SCAs: type I densely granulated SCAs and type II sparsely granulated SCAs. Both are associated clinically with a more aggressive behavior compared with functional CD adenomas [13] . POMC mRNA levels in type I SCAs are similar to those found in CD, while levels in type II SCAs are lower [19] .
Molecular pathology
Since the first description of SCAs by Kovacs et al. almost 40 years ago [20] , researchers have tried to unravel the molecular mechanisms underlying tumorigenesis, progression, and growth of this unique non-functioning pituitary corticotroph adenoma. Several hypotheses have been developed to explain the inability of SCA to create a state of clinical hypercortisolism coupled with their more aggressive growth that stands in sharp contrast to CD and despite expression of ACTH in both adenoma types. To date, however, studies into cell origin, different sensitivity to hypothalamic stimulants, lysosomal dysfunction, regulation of POMC cleavage efficiency, and cell cycle regulation are merely associative and remain to be proven.
Mechanisms of pathogenesis and differentiation
The origin of the adenoma corticotroph cells may determine tumor type. It has been suggested that SCAs derive from the human pars intermedia POMC-positive cells which, unlike in other animals, invade and scatter throughout the human anterior lobe of the pituitary gland, while CDs derive from anterior pituitary lobe corticotroph cells [17] . Reduced retinoblastoma transcriptional corepressor 1 (RB1) expression promotes the development of pituitary tumors, especially in mouse intermediate lobe; mice conditionally depleted of RB1 develop murine SCA originating from paired box 7 (PAX7)-expressing pituitary progenitor cells that reside only in the intermediate lobe but can migrate to the anterior pituitary. PAX7 was shown to be expressed in human neoplastic corticotroph cells, and cells harboring both PAX7 and α-melanocyte stimulating hormone (MSH) are highly expressed in the macaque and human intermediate lobe [21] . These data further support the hypothesis that the origin of the corticotroph, whether from the anterior or the intermediate pituitary lobe, determines whether CD adenoma or SCA will develop, respectively.
A potential cause for the silent nature of ACTH in SCAs was demonstrated on electron microscopy, which shows most SCA cells exhibiting multiple dark lysosomes of various sizes, fusion of secretory granules with lysosomes, and extensive disposal of granules by lysosomes and autophagy [20] . This observation may imply that either lysosome dysfunction or abnormal ACTH synthesis drives the cells to destroy ACTH before it is secreted [20] . As the POMC gene was not shown to be mutated in SCA [22] , this hypothesis may be further validated.
Yet another hypothesis focuses on differences in posttranslational processing of pituitary hormone by prohormone convertase (PC) 1/3, which cleaves ACTH from the POMC polypeptide. In the non-neoplastic pituitary, these enzymes can be found in corticotrophs, gonadotrophs, and thyrotrophs. Several investigators demonstrated differences in PC1/3 expression between CD and SCA, suggesting that this enzyme may play a role in determining whether a corticotroph adenoma will be secreting or non-secreting. CD adenomas express high levels of PC1/3 [23] but PC1/3 protein is not expressed by SCA, even though low levels of its mRNA, equal to those found in other non-functioning pituitary tumors, can be detected. It is therefore thought that defective PC1/3 post-transcriptional regulation of POMC is responsible for the lack of ACTH secretion from SCAs [15, 24] . Indeed, 2 SCAs showing elevated serum ACTH but not cortisol immunostained negative for PC1/3 while 16 functioning corticotroph adenomas expressed high levels of the enzyme [25] .
Intriguingly, there is evidence that corticotroph adenomas can transform from SCA to CD and vice versa, although such transformations are rare [26] . A recent study demonstrated that over 15 years of follow up, only 7 (3.9%) of 176 ACTH-immunopositive adenomas showed signs of transformation on histology (5 adenomas transformed from SCA to CD and 2 transformed from CD to SCA). PC1/3 protein and mRNA levels increased in 3 adenomas that transformed from SCA to CD adenoma, further supporting the association between PC1/3 levels, ACTH secretion, and the development of clinical hypercortisolism ( Fig. 1 ) [26] . Nevertheless, it is as yet unclear whether PC1/3 regulation determines whether a corticotroph adenoma will be functional, and, if yes, which mechanisms regulate PC1/3 expression.
The possibility that corticotroph adenoma sensitivity to hypothalamic stimulants underlies functional status has also been studied. Comparing 12 CD adenomas and 8 SCAs, mRNA expression levels of corticotrophin releasing hormone receptor 1 (CRHR1) and vasopressin V1b receptor (V1BR) were decreased in SCA as compared to CD, suggesting the latter exhibit an increased response to these hypothalamic stimulators. Somatostatin receptor (SSTR)1 and SSTR2 mRNA expression is higher in SCA than in CD adenoma, suggesting increased response to the inhibitory effect of hypothalamic somatostatin-14, while SSTR5 mRNA expression is lower in SCA and expression of SSTR3 and dopamine receptor D2 (DRD2) is similar in SCA and CD adenoma [27] . By contrast, DRD2 mRNA expression was shown to be lower in 7 SCAs than in 76 other nonfunctioning adenomas (null, plurihormonal, and gonadotroph) [28] .
Although these findings offer insight into some of the key characteristics of SCAs, as mRNA protein expression as well as protein function do not always positively correlate, interpretation of mRNA level and its effects on protein function should be considered with caution.
Mechanisms of SCA progression and growth
Attempts to explain the aggressive growth rate of SCA are limited and inconclusive, and reasons underlying their propensity for recurrence are poorly understood. Comparing 10 CD adenomas and 11 SCAs, SCA showed lower mRNA and protein expression of cyclin-dependent kinase inhibitor 2A (CDKN2A), also known as p16 INK4a , as well as higher cyclin D1. This combination of reduced CDKN2A and increased cyclin D1 prevents G1 phase cell cycle arrest in pituitary tumors and allows for further cell proliferation; the investigators thus propose that this may explain why SCAs are larger than CD adenomas [29] . Ki-67, a marker of cell proliferation, was not shown to be elevated, and remained < 3% in a series of 39 SCAs studied, regardless of whether they recurred [11] . Similarly, no correlation was demonstrated between Ki-67 and cavernous sinus extension in SCA or in gonadotroph or null cell adenomas [9] . Therefore, Ki-67 does not appear to be helpful in determining SCA aggressiveness and probably cannot be relied upon for tumor behavior prediction.
Markers of cell growth and survival, including galectin-3, kallikrein 10 (KLK10), osteopontin and the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT) were also compared in CD adenomas and SCAs. Although differences were demonstrated, a clear role for these mechanisms in SCA tumorigenesis and growth was not shown. Galectin-3, a β-galactoside binding protein, is a member of the lectin family and was shown to be involved Based on data from Righi [26] 1 3 in cell adhesion, growth, differentiation, and apoptosis, and, in certain non-pituitary tumors, to be positively associated with tumor aggressiveness [30] . Galectin-3 expression was surprisingly higher in CD than in SCA. Comparing 19 CD adenomas and 11 SCAs, galectin-3 protein immunoreactivity was positive in 95% of CD adenomas but negative in 82% of SCAs. Expression was seen in a mean of 77% of cells in each CD adenoma compared with only 9% in each SCA, with 9/11 adenomas immunostaining for galectin-3 in < 1% of cells. Galectin-3 expression is limited to normal corticotroph, lactotroph, and folliculostellate cells, but is also seen in prolactinomas and CD adenomas [31] . [31] . Thus, the absence of galectin-3 in SCA biologically positions it somewhere between NFA, which express lower levels of galectin-3, and CD adenoma, which express higher levels. Although the direct effect of galectin-3 absence on SCA behavior is not clear, it can serve as a marker to differentiate SCA from CD adenomas [18] .
The human tissue kallikrein family participates in tumor progression, invasion, and metastasis. KLK10 is a serine protease thought to also act as a tumor suppressor given its ability to inhibit tumor formation in nude mice. On immunohistochemistry, KLK10 protein expression was significantly higher in CD adenomas than in SCAs. Moreover, the staining pattern differed: while KLK10 staining was observed in both nucleus and cytoplasm in CD adenomas, only cytoplasmic distribution was observed in SCAs, an observation with an as yet unclear biological relevance. Reduced expression of KLK10 in SCAs is consistent with the larger size of these adenomas, and may also serve as a marker to distinguish them from CD adenomas [32] .
Osteopontin, an extracellular matrix-associated sialic acid-rich phosphoglycoprotein, which was shown to associate with invasiveness of several non-pituitary malignant tumors by increasing cell migration, motility, and invasiveness, may also be associated with increased SCA aggressiveness as compared with gonadotroph adenomas. In one series, all 19 SCAs examined expressed osteopontin and at a higher intensity compared with only 42% of 50 gonadotroph adenomas that exhibited lower staining intensity [33] .
MGMT protects against cytotoxicity from alkylating agents such as temozolomide, so lower level of expression in the adenoma is associated with better outcomes following treatment. On IHC, 7 of 7 SCAs tested showed MGMT expression levels < 10% while only half of 46 CD adenomas expressed such low levels [34] . Clinical outcomes following temozolomide treatment in SCA are discussed in the next section.
Recently, ubiquitin-specific protease 8 (USP8) gain-offunction mutations were discovered in CD adenomas [35, 36] . USP8 was shown to protect the epidermal growth factor receptor (EGFR) from degradation by removing ubiquitin residues from the receptor protein [37, 38] , and treatment with the EGFR inhibitor gefitinib reduces POMC mRNA and protein expression in mouse corticotroph cells [39] . However, while 48/134 (36%) of CD adenomas were positive for USP8 mutations, mutations were not identified in 11 SCAs analyzed [36] .
SCAs and gonadotroph cell markers
Estrogen receptor subtype α and β are expressed in low levels in both SCAs and CD adenomas, despite the higher prevalence of CD adenomas in females [40] . Interestingly, in post mortem analysis of 3 of 4 females with primary ovarian failure due to 45X karyotype causing Turner syndrome, small corticotroph adenomas were discovered rather than gonadotroph tumors, despite chronic and excessive positive feedback on gonadotroph cells [41] . These cells stained positive for ACTH and did not show Crooke's hyalinization. None of the patients had CD, and the adenomas were therefore classified as SCAs. The authors speculated that gonadotroph-to-corticotroph transdifferentiation may have occurred, or corticotrophs harboring GnRH receptors may have undergone neoplastic transformation. It is also possible that the genetic abnormality in Turner syndrome causes corticotroph adenoma development directly via as yet unknown mechanisms [41] .
Further linking SCAs and gonadotroph cell markers, we showed that SCAs manifest both corticotroph and gonadotroph cytologic features [42] . Comparing 18 SCAs, 23 gonadotroph adenomas, and 11 CD adenomas on fluorescent IHC, we showed that all SCAs express the corticotroph markers ACTH and NeuroD1 in addition to the gonadotroph markers steroidogenic factor-1 (SF1) and nuclear receptor subfamily 0 group B member 1 (NR0B1, which encodes DAX1), and 78% also expressed α-GSU; some cells coexpressed ACTH and SF1. In contrast, only 33% of CD adenomas expressed α-GSU and DAX1 and 80% expressed SF1. All gonadotroph adenomas expressed SF1, DAX1, and NeuroD1. TPIT expression was positive in 44% of SCAs, 100% of CD adenomas, and none of the gonadotroph adenomas. The discrepancy between our TPIT immunostaining rate of SCAs and other papers that showed 100% immunostaining may derive from TPIT antibody, which is known to be challenging [13] , as well as differences in adenoma fixation and staining protocols. Given these findings, we proposed that SCA derives from an intermediary cell that shares corticotroph and gonadotroph features [42] . Clinical implications of this finding remain to be elucidated.
Clinical course

Clinical presentation
SCAs present as NFAs with symptoms of headaches, visual field impairment, and hypopituitarism [4, 6, 42] , but differences between the two tumor types have been noted. In one series, a significantly higher rate of visual dysfunction was seen among patients with SCAs, and 25% of SCAs presented with pituitary apoplexy compared to 8% in NFAs [6] . Some series found higher rates of preoperative hypopituitarism, especially hypogonadism, in patients with SCAs [43] . Pooling data across reported series (Table 1 ), 38% of patients had preoperative hypopituitarism, with rates varying from 11 to 76%. By contrast, hyperprolactinemia may be observed in both SCAs and NFAs at similar rates [6, 43] .
Some studies show a female preponderance in SCAs compared with NFAs [6, 9, 12] while others do not [4, 11, 42, 48, 49] . Age at presentation is typically similar to NFAs [4, 6, 42, 48] , although some have observed SCAs presenting at younger ages [11] , with surgery occurring in one series in the 5th and 6th decades compared to the 6th and 7th decades for NFAs [43] .
Preoperative diagnosis
Diagnosis of SCAs is generally made postoperatively on confirmation of pathologic staining for ACTH. Attempts to diagnose SCAs preoperatively have shown mixed results. While some series found that SCAs may have elevated ACTH levels with normal cortisol levels [5, 11, 15, 44, 45, 51] , others did not find differences in preoperative ACTH and cortisol levels compared to NFAs [6, 52] . One group that conducted preoperative assessments of ACTH, urinary free cortisol (UFC), and salivary cortisol on all patients undergoing pituitary adenoma resection found that, of the 20/124 (16%) confirmed corticotroph tumors, 8 were clinically silent, with patients showing no Cushingoid features but having elevated 24-hour UFC or ACTH. Five were totally silent, with patients showing no Cushingoid features and normal biochemistries, and 2 were unclassified [2] . Patients with SCAs may secrete high-molecular-weight ACTH, which can be detected on routine ACTH assays [53, 54] .
Radiologic features
SCAs may present as pituitary incidentalomas [47] , and appear similar to NFAs [4] , with similar tumor size [4, 6, 11, 42, 43, 48, 49] , although one series comparing the two tumor types found that 23% of 126 NFAs presented as incidentalomas while none of the 33 SCAs did [43] . Some have observed that SCAs manifest more cysts on magnetic resonance imaging (MRI) [6] , with up to 75% having multiple microcysts on T2-weighted MRI, although microcysts have been noted in 90% of null cell and 80% of gonadotroph adenomas as well [2] . Overall, 43% of SCAs present with cavernous sinus invasion (Table 1) ; rates may be higher in SCAs than in NFAs [4, 9, 12] or they may be similar [6, 11, 42, 49] . SCAs also may have more intratumoral hemorrhage compared with NFAs [6, 48] .
Postoperative course
Pooled results of 368 reported cases (Table 1) show that new-onset postoperative hypopituitarism in SCAs has been observed in 35% of cases (range 17-77%), and 27% (range 0-59%) show recurrent tumor.
Reported recurrence rates vary widely, possibly due to length of follow-up and sample size numbers, and potentially also due to the use of adjuvant radiotherapy in some patients, which may have affected outcomes. Data from 11 case-controlled studies suggest higher recurrences in SCAs compared to NFAs, supporting the view that SCAs pursue a more aggressive clinical course [3, 4, 6, 9, 11, 12, 42, 43, 46, 48, 49] . However, few studies reported predictors of recurrence. Tumor size, cavernous sinus and/or sphenoid sinus invasion, and positive ACTH immunostaining have been associated with more surgeries in patients with SCAs than in those with ACTH immunonegative tumors [11] . Of note, higher recurrence rates were observed in subtype I than in subtype II SCAs in one series [4] , although others have not demonstrated this [7, [44] [45] [46] . Finally, it was shown that SCAs may recur 5 years earlier than NFAs, especially with de novo recurrences, independent of initial tumor diameter; by contrast, NFA recurrences correlated with initial tumor size [42] .
Bradley et al. found that SCAs had a 32% recurrence rate, similar to that of NFAs, even after excluding those who were irradiated [46] . By contrast, in Yamada's series, despite higher rates of cavernous sinus invasion noted in SCAs (85 vs. 38%), there were no observed recurrences in either group, although follow-up time was short [9] . Pawlikowski et al. found that 35% of SCAs recurred compared to 14.7% of NFAs, which they suggested may be due to higher rates of Ki-67 and atypia [3] . Cho et al. found that both SCAs and NFAs had similar recurrence rates of 25%, even when excluding patients who underwent radiation therapy (RT), and despite SCAs having more cystic and hemorrhagic components, although size and rates of invasion did not differ. However, multiple recurrences (> 2) occurred in 57% of SCAs compared to 2.8% of NFAs, and the tumors showed lower rates of ACTH immunostaining. Interestingly, SCA recurrence occurred at a younger age compared to NFA Higher Ki-67 and atypia in SCAs
Cho [6] recurrences [6] . In our series, we found similar rates of residual tumor growth in SCAs (56%) and NFAs (59%), but higher rates of de novo recurrences in SCAs (25%) compared to NFAs (2%), and the overall number of recurrences was also higher in SCAs [42] . Alahmadi et al. found a low 14% recurrence rate in SCAs, similar to that in NFAs, although SCAs showed more tumoral hemorrhage [48] . In Ioachimescu's series, SCAs and NFAs with similar preoperative size and radiologic invasion had similar rates of recurrence, with progression of residual tumor seen in 47% of SCAs vs. 23% of NFAs and de novo recurrence in 13 and 11%, respectively. Of note, both cohorts experienced similar rates of reoperation and RT use [43] . In Jahangiri's study, 27% of SCAs recurred compared to 7% of NFAs (p < 0.001), with similar rates in type I vs. type II SCAs. However, 3-year progression was higher among SCAs compared to NFAs, and 34% of type I SCAs recurred at 3 years compared to 10% of type II SCAs, both of which were significantly different from NFA rates. Predictors of recurrence in this study included tumor size, with a hazard ratio of 2.9 [4] . Cohen-Inbar et al. found that 18% of SCAs progressed after RT compared to 5.9% in NFAs (p = 0.0065) and ACTH staining was shown to predict tumor progression, with a hazard ratio of 2.6 on multivariate analysis [49] . Finally, Langlois reported 36% of SCAs recurred compared to 10% of NFAs (p = 0.001). Of note recurrent SCA tumors were more likely to be larger and to be type I, and to show higher ACTH levels and radiologic invasion. Presence of cavernous sinus invasion increased the likelihood of recurrence threefold [11] .
Despite their silence, SCAs may affect pituitary function postoperatively. Postoperative functional assessment of the hypothalamus-pituitary-adrenal axis in the immediate postoperative period and at 3 months showed similar levels of ACTH, dehydroepiandrosterone-sulfate, and cortisol secretion in SCAs and NFAs in one study [52] , but others report higher rates of new-onset hypopituitarism in SCAs, namely from adrenal insufficiency [11] and hypothyroidism [42] , and some observed no increased risk of postoperative hypopituitarism [6] . We found development of postoperative hypopituitarism was associated with increasing tumor size in NFAs but no similar association with size was noted in SCAs [42] . This may suggest that tumoral corticotrophs secrete some amount of ACTH locally, leading to ACTH suppression in normal corticotrophs. After resection of the SCA, the normal corticotrophs may then remain suppressed until they recover.
Higher rates of hypopituitarism, especially adrenal insufficiency, may also result from inclusion of SCAs that manifest subclinical Cushing disease or cyclical Cushing's syndrome. Only one study conducted comprehensive preoperative cortisol assessments in all patients undergoing pituitary surgery, but the authors did not report rates of postoperative adrenal insufficiency [2] . In some series, a few patients developed postoperative adrenal insufficiency despite normal preoperative cortisol levels [45, 47] , and another study performed cortisol testing if patients had elevated ACTH levels, although it is unclear whether these were the patients subsequently reported to have developed adrenal insufficiency after surgery [11] . Thus, although it is possible that at least some patients with SCAs had subclinical or cyclical Cushing's syndrome, there are insufficient data to draw such a conclusion, likely because these tumors present as NFAs and patients therefore do not undergo routine testing for hypercortisolism. Differences between SCAs and NFAs have also been reported in other postoperative outcomes. One study observed that patients with SCAs had a higher mortality than did those with NFAs, with rates of 15% compared to 4%; 4 SCA patients died of tumor progression, but cause of death was unclear in the remaining patients [43] . Of note, a study of 385 patients with NFAs did not observe an association between ACTH immunopositivity and mortality [55] , but other studies reporting on mortality in NFAs do not report ACTH staining results [56] [57] [58] [59] .
As noted above, there is evidence of SCA transformation to functioning CD adenoma. While there are case reports of this phenomenon [8, [60] [61] [62] [63] [64] [65] , it is a rare occurrence in larger series, with rates of 0-9% of SCAs transforming [4, 10, 11, 43, 45, 66] . Finally, there is concern that SCAs may develop into carcinomas [44, [67] [68] [69] [70] [71] [72] , but this, too, may be rare.
Treatment options
The more aggressive postoperative course with SCAs compared with NFAs suggests that RT could be considered at an earlier time point. In a study of 170 NFA patients treated with Gamma Knife stereotactic radiosurgery (SRS), 42% of the 34 patients with SCA showed tumor progression compared with 10% of NFA patients. Benefit was observed at doses > 15 Gy. Progression-free survival rates were 84% at 3 years and 52% at 8 years in SCA patients compared with 97% at 3 years and 89% at 8 years in NFA patients [73] . Similarly, in a multicenter study in which enrolled patients with NFAs were treated with Gamma Knife SRS, 18% of SCAs progressed after treatment and had a tumor control rate of 82%; by contrast, only 5% of NFAs showed tumor progression and 94% were controlled. Increased radiotherapy margin dose predicted adenoma progression in both tumor types, and SCAs with positive ACTH staining had a higher hazard ratio for progression [49] .
Conventional RT has also been used in the treatment of SCA, and some have recommended adjuvant RT in these patients [8, 43] . However, results are mixed. In Baldewag's series of 15 SCAs, 6 patients underwent fractionated RT and 4 still showed recurrence [8] . Cho et al. treated 4 SCAs with conventional RT, and recurrence rates after therapy did not differ between RT-treated SCAs and NFAs [6] . Langlois et al. treated more SCAs than NFAs with RT, but it is unknown whether this affected recurrence rates [11] . Of note, in Webb's series of 27 SCAs, 2 patients underwent conventional RT and 7 underwent SRS, and the authors observed that 42% of those who did not receive RT had recurrences compared to 11% who underwent RT [45] . Pooling together studies that report on RT and recurrence rates, 25% of the 107 SCAs treated with conventional RT or SRS recurred compared to 35% of the 145 not irradiated [6, 8, 43, 45, 49] .
The molecular characteristics of SCAs suggest that targeted therapies may be an option. As noted above, SSTR1 and SSTR2 mRNA expression is higher in SCAs than in CD adenomas, and expression of SSTR3 and DRD2 is similar in the two tumor types [27] . Nevertheless, it remains to be seen whether dopamine agonists and somatostatin receptor ligands will show clinical benefit in patients with SCAs as they do in those with CD adenomas. Finally, there was one report of stable disease after use of bevacizumab therapy in an aggressive SCA carcinoma that showed vascular endothelial growth factor immunoreactivity [72] .
Cytotoxic chemotherapy may also be useful in aggressive SCAs and SCA carcinomas. As noted above, SCAs may show low to absent MGMT immunostaining [34] , suggesting temozolomide may be beneficial. However, while some have observed partial response in these tumors to temozolomide [74] , others have shown poor responses in SCA carcinomas [67, 69, 75] and one study showed that having an initially silent tumor was associated with being a nonresponder to temozolomide [76] . Addition of capecitabine has been shown improve response to temozolomide [77] , and the combination of carboplatin and etoposide yielded disease stabilization in an SCA carcinoma and regression of leptomeningeal deposits [68] .
Conclusions
SCAs are pituitary adenomas that are biologically and clinically distinct from both functioning CD adenomas and NFAs. Approximately one-third of patients harboring these aggressive macroadenomas may develop new-onset hypopituitarism and show tumor recurrence, underscoring a need for close monitoring in the postoperative period. Transformation to CD adenoma and to SCA carcinoma have also been reported and may prove challenging to diagnose and treat. Studies of molecular mechanisms underlying SCA tumorigenesis, pathogenesis, and growth will help better characterize SCAs and define new, more effective approaches for multimodal therapy.
